If You Invested $1000 In Waters Stock 20 Years Ago, You Would Have This Much Today
Waters (NYSE:WAT) has outperformed the market over the past 20 years by 2.82% on an annualized basis producing an average annual return of 12.05%. Currently, Waters has a market capitalization of $41.46 billion. Buying
Benzinga7 gün önceWAT
Is Wall Street Bullish or Bearish on Waters Corporation Stock?
Although Waters Corporation has exceeded the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.
Yahoo7 gün önceWAT
This Waters Analyst Turns Bullish; Here Are Top 3 Upgrades For Thursday
Top Wall Street analysts upgraded BWX Technologies, The Macerich Company, and Waters Corporation. Check out analyst ratings and price targets.
Benzinga8 gün önceWAT
Piper Sandler Upgrades Waters to Overweight, Raises Price Target to $480
Piper Sandler analyst David Westenberg upgrades Waters (NYSE:WAT) from Neutral to Overweight and raises the price target from $400 to $480.
Benzinga8 gün önceWAT
Research Tools & Consumables Stocks Q2 Highlights: Waters Corporation (NYSE:WAT)
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Waters Corporation (NYSE:WAT) and the rest of the research tools & consumables stocks fared in Q2.
Yahoo8 gün önceWAT
Waters Corporation to Present at the Wells Fargo Healthcare Conference
Waters Corporation (NYSE: WAT) announced that Udit Batra, Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9th, 2026, at 10:15 AM Eastern Time.
Yahoo9 gün önceWAT
Qiagen names Jonathan Pratt as CEO amid takeover talks
Investing.com -- Qiagen N.V. (NYSE:QGEN) announced Monday that Jonathan M. Pratt will become chief executive officer on September 1, 2026, as the molecular testing company continues discussions with potential buyers.
Yahoo11 gün önceWAT
Agilent Stock Has A Catalyst Coming On August 26 That Investors Should Not Ignore
Agilent Technologies has a company-confirmed earnings report dropping after the close on August 26, and every operating lever heading into that date is pointing the same direction. Here is what retirement-focused investors need to understand before the bell rings.
Yahoo14 gün önceWAT
1 Unpopular Stock That Deserves a Second Chance and 2 That Underwhelm
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
Yahoo17 gün önceWAT
The 5 Most Interesting Analyst Questions From Waters Corporation’s Q2 Earnings Call
Waters Corporation’s Q2 results were met with a positive market reaction, driven by strong organic growth and momentum from its recently acquired Biosciences and Diagnostic Solutions businesses. Management pointed to robust demand across pharmaceutical, academic, and government markets, as well as the successful integration of new product launches. CEO Udit Batra highlighted that, "GLP-1 testing part of the business grew over 40% this quarter," with broad-based contributions across regions. The
Yahoo22 gün önceWAT
Waters (WAT) Q2 2026 Earnings Call Transcript
Organic growth accelerated to 9% as acquired units and legacy markets recovered.
Yahoo24 gün önceWAT
1 Surging Stock with Competitive Advantages and 2 We Turn Down
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
Yahoo24 gün önceWAT
Citigroup Maintains Buy on Waters, Raises Price Target to $470
Citigroup analyst Joanne Wuensch maintains Waters (NYSE:WAT) with a Buy and raises the price target from $425 to $470.
Benzinga25 gün önceWAT
Waters Q2 Earnings Call Highlights
Waters (NYSE:WAT) reported second-quarter 2026 revenue of $1.645 billion, driven by 9% organic constant-currency growth and a 4% increase in revenue from its acquired Biosciences and Diagnostic Solutions businesses. The company raised its full-year outlook for organic revenue, acquired-business reve
Yahoo26 gün önceWAT
Waters (WAT) Launches Xevo TQ Absolute XR IVD For Clinical Labs
Waters (NYSE: WAT) introduced the Xevo TQ Absolute XR IVD Mass Spectrometer, a new clinical laboratory system with high analytical sensitivity and robustness. The instrument targets critical clinical applications, including hormone testing and toxicology workflows. The launch expands Waters' clinical diagnostics product lineup at a time when demand for precise mass spectrometry tools in healthcare remains a key focus for laboratories. Consider exploring other companies supplying the tools...
Yahoo27 gün önceWAT
Waters Corporation 2026 Q2 - Results - Earnings Call Presentation
2026-08-07. The following slide deck was published by Waters Corporation in conjunction with their 2026 Q2 earnings call.
SeekingAlpha27 gün önceWAT